Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis

Gunduz Z., Kisaarslan F., Dusunsel R., Poyrazoglu H., Saraymen R., Per H.

19th Annual Conference on Peritoneal Dialysis, Charlottetown, Canada, 28 February - 02 March 1999, vol.15, pp.278-282 identifier

  • Publication Type: Conference Paper / Full Text
  • Volume: 15
  • City: Charlottetown
  • Country: Canada
  • Page Numbers: pp.278-282
  • Istanbul Technical University Affiliated: No


We studied tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) levels in plasma and peritoneal effluent in 10 children on continuous ambulatory peritoneal dialysis (CAPD) before. and 8 and 12 weeks after; treatment with recombinant human erythropoietin (rHuEPO). Plasma t-PA and PAI-1 levels It ere lower in patients than in controls during the study The plasma t-PA levels were increased by rHuEPO treatment. Although PAI-1 levels showed a tendency to increase in the early phase of rHuEPO treatment, they later returned to near baseline levels. Peritoneal effluent t-PA levels were decreased at week 8 of treatment, but returned ro baseline levels at week 12. Peritoneal effluent PAI-1 levels were not changed by the rHuEPO treatment. No can-elation was observed between levels of t-PA and PAI-1 in plasma and in peritoneal effluent. No correlation was seen between plasma PAI-1 levels and duration of CA PD. A significant negative correlation was found between the plasma PAI-I levels and hemoglobin levels at week 8 and week 12. These results suggest that plasma t-PA levels can be increased by rHuEPO treatment, while plasma PAI-1 levels are associated with hemoglobin levels.